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Background: To assess the therapeutic outcome and failure pattern of three-dimensional conformal radiotherapy
(3D-CRT)-based concurrent chemoradiotherapy (CCRT) for recurrence of esophageal squamous cell carcinoma (SCC)
after radical surgery.
Methods: Treatment outcome and failure pattern were retrospectively evaluated in 83 patients with localized cervical
and thoracic recurrences after radical surgery for thoracic esophageal SCC. All patients were treated with 3DCRT-based
CCRT (median radiation dose 60 Gy), in which 39 received concurrent cisplatin plus 5-fluorouracil (PF), and 44 received
concurrent docetaxel plus cisplatin (TP). Treatment response was evaluated at 1–3 months after CCRT.
Results: With a median follow-up of 34 months (range, 2–116 months), the 3-year overall survival (OS) of all the
patients was 51.8% and the median OS time was 43.0 months. The overall tumor response rate was 75.9% (63/83), with
a complete remission (CR) rate of 44.6% (37/83). In univariate analysis, tumor response after CCRT (p = 0.000), recurrence
site (p = 0.028) and concurrent chemotherapy (p = 0.090) showed a trend favoring better OS. Multivariate analysis
revealed that tumor response after CCRT (p = 0.000) and concurrent chemotherapy (p = 0.010) were independent
predictors of OS. Forty-seven patients had progressive diseases after CCRT, 27 had local failure (27/47, 57.4%), 18
had distant metastasis (18/47, 38.3%) and 2 had both local and distant failures (2/47, 4.3%).
Conclusions: 3DCRT-based CCRT is effective in postoperatively recurrent esophageal SCC. Patients that obtained
complete remission after CCRT appeared to achieve long-term OS and might benefit from concurrent TP regimen.
Local and distant failures remained high and prospective studies are needed to validate these factors.
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Esophageal cancer (EC) remains one of the most fatal
malignancies in the world. In 2005, about 497,700 new
cases occurred worldwide, and the prevalence is expected
to increase by approximately 140% by 2025 [1]. Unlike
western countries, in China the predominant histological* Correspondence: liuhuisysu@yahoo.com
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reproduction in any medium, provided the orsubtype of EC is squamous cell carcinoma (ESCC), and
tumors are more likely to develop in the middle and upper
thoracic esophagus [2,3]. Surgical resection is the primary
treatment for thoracic ESCC in many cancer institutes
as it offers a chance of cure. Although the 5-year overall
survival rates of patients who underwent curative tumor
resection range from 31 to 55% [4,5], postoperative
recurrence remains the major type of failure. The recur-
rence rate of surgical patients ranges from 36 to 56%
and the median time to recurrence ranges from 10 to
12 months; while anastomosis, regional (mediastinum
and upper abdomen) lymph node and supraclavicular. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6-8]. Significant difficulty is often encountered in
determining treatment options for recurrent disease
after esophagectomy, and patient prognosis is generally
poor [9-11].
Although optimal treatment for patients with postop-
erative recurrence of ESCC has remained controversial,
recent advances in anticancer drug and radiation tech-
niques may help to improve treatment outcomes. Since
these patients hadn’t received radiotherapy (RT) or chemo-
therapy before, RT combined with concurrent chemother-
apy might have a beneficial symptomatic effect and a
possibility to obtain long-term survival [12-16]. Thus, the
factors affecting this survival after postoperative recurrence
in ESCC patients need to be fully explored. In our study,
we evaluated the prognostic factors and treatment failure
pattern of concurrent chemoradiotherapy (CCRT) for
postoperative recurrence of ESCC.
Methods
Acquisition of clinical data
We retrospectively reviewed the records of 83 consecu-
tive patients treated with three- dimensional conformal
radiotherapy (3D-CRT)-based CCRT for postoperative
recurrence of ESCC between June 2001 and December
2010 in the Sun Yat-Sen University Cancer Center. Patients
recruited in our study had: R0 resection (no residual
microscopic disease) for primary ESCC with 2-field or
3-field lymphadenectomy; cervical and/or thoracic post-
operative recurrence (biopsy proven or 3-month follow-up
CT showed subsequent development of disease); no
distant organ metastasis or abdominal lymphadenop-
athy; no history of RT or chemotherapy; ECOG per-
formance ≤3.
Clinical data collected for each patient included age,
sex, thoracic surgery history, primary esophageal tumor
location, stage and histology of primary ESCC, Eastern
Cooperative Oncology Group (ECOG) performance status,
interval time between surgery and recurrence, recur-
rence sites, histology of recurrent lesions, irradiation
dose, concurrent chemotherapy regimens and tumor
response to CCRT. The 7th edition of American Joint
Committee on Cancer (AJCC) staging system for
esophageal cancer released in 2010 was used to restage
the primary diseases after radical surgery. Written in-
formed consent was obtained from the patient for the
publication of this report and all accompanying images.
Treatment
Our techniques for patient immobilization, simulation and
treatment planning were performed according to standard
protocol for esophageal carcinoma receiving 3-DCRT in
our department [17]. With the patient in supine position,
a cradle for immobilization was made with vacuum.Individual patient was scanned from the Atlas (C1) to the
second lumbar vertebra (L2) level to cover the whole neck,
lung, esophagus and celiac lymph node regions. CT scan
was performed with 0.5 cm thickness slices. Briefly, the
gross tumor volume (GTV) consisted of recurrent lesion
diagnosed by biopsy or subsequent CT scan; the regions of
tumor described on endoscopy but not seen on CT were
also included in the GTV. To minimize interobserver vari-
ability, CT scans of all patients were reviewed by a single
radiologist (Dr. PeiQiang Cai). The criteria of lymph node
positivity on the CT scan were: short axis size ≥ 10 mm,
lymph node with infiltrative margin, or central necrosis
[18]. The clinical target volume (CTV) of patients com-
prised the anastomosis, supraclavicular, and station 1–5
and 7 lymph nodes [19]. Two planning target volume
(PTV) had been defined. PTV1 was defined as the GTV
plus a 0.5 cm margin and PTV2 was defined as the CTV
plus a 0.5 cm margin in all direction, respectively. All pa-
tients had 3D-CRT treatment plan calculated by Pinnacle
planning system, and treated with a 6-MV linear acceler-
ator. The median dose was 60 Gy to PTV1 (range from
56-68 Gy), and 46 Gy to PTV2 (range from 40 to 54 Gy).
Dose constraint for critical organs: spinal cord < 46 Gy,
mean lung dose < 17 Gy and V20 <30%.
Forty-two patients were treated with 2 cycles of cisplatin
and 5-fluorouracil concurrently with RT. 18 patients re-
ceived chemotherapy consisted of 60 mg/m2 of cisplatin
administered on Days 1 and 29, 300 mg/m2/24 h of 5-Fu
administered on Days 1 to 3 and Days 29 to 31. Twenty-
two patients received cisplatin and 5-fluorouracil regimen
consisted of 30 mg/m2/day cisplatin and 500 mg/m2/day
5-Fu administered on Days 1–5 and 29–33. Another 41
patients were treated docetaxel-based regimens, 26 with
2 cycles of docetaxel and cisplatin, the regimen containing
60 mg/m2 docetaxel on Days 1 and 29, and 80 mg/m2
cisplatin on Day 1 and 29 [17]; 15 with concurrent
chemotherapy comprising cisplatin 30 mg/m2 and do-
cetaxel 30 mg/m2 weekly for 4–6 weeks [20,21]. The
chemotherapy regimens were subsequent institutional
standards with PF earlier and taxanes later. Supportive
therapy was administered by clinical dietitian, and pa-
tients had been evaluated by NRS2002 since 2003.
Follow-up and response assessment
The beginning of the follow-up period was defined as
the last date of CCRT treatment. Patients underwent
chest CT scan every 3 months, upper digestive tract en-
doscopy and abdominal ultrasonography every 6 months
for 2 years after the CCRT, and then chest CT scan, en-
doscopy and abdominal ultrasonography every 6 months
for another 3 years. Bone scan was administrated when
patients were suspected for bone metastasis. Rates and
times of treatment response, overall survival, local re-
lapse and distant metastasis were recorded.
Table 1 Characteristics of patients














Three-field resection 11 (13.3%)
Two-field resection 72 (86.7%)
Histology of primary tumor (SCC)
G1-2 50 (60.2%)
G3-4 33 (39.8%)








Anastomosis with/without lymphadenopathy 20 (24.1%)
Supraclavicular and/or regional lymph node 63 (75.9%)
RT dose (Gy), median (range) 60 (50–68)
Concurrent chemotherapy
cisplatin + 5-Fu 39 (47.0%)
Docetaxel + cisplatin 44 (53.0%)
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3 months after CCRT. Tumor response was recorded
according to the definition of Response Evaluation
Criteria In Solid Tumors (RECIST). Complete response
for the recurrent anastomotic tumor was defined upon
endoscopic observation as disappearance of the tumor
lesion, ulceration, and absence of cancer cells in biopsy
specimens. Complete response for lymph nodes was
defined according to the RECIST as the complete dis-
appearance of the lymph nodes. However, lymph nodes
of <5 mm or residual connective tissue after disappear-
ance of cancer with no evidence of progression after com-
pletion of treatment were regarded as noncancerous tissue
[22]. Multiple failures comprised both local and distant
failures after CCRT.
Statistical analysis
The study endpoint was overall survival (OS). OS was
calculated as the time from the last date of radiotherapy
to the date of death from any cause or to the last visit
before April 31, 2011, censored at the date of last follow
up. Continuous variables such as age, interval time
between surgery and CCRT, RT dose were discretized at
the sample median and then analyzed as nominal categor-
ical variables. Each variable was assessed first in a univari-
ate analysis and the variables that reached a P value <0.10
were evaluated in a multivariate analysis. Survival curves
were plotted using the Kaplan-Meier method. We fitted
the proportional hazards model using Cox regression.
After testing for variable interactions, a forward step-
wise elimination procedure was used to determine the
best-fitting model. P values <0.05 were regarded as
statistically significant in multivariate analysis. All stat-




Patient characteristics are detailed in Table 1. The
study included 83 patients and comprised 21 female
and 62 male. Seventy-three patients (88.0%) had ECOG
performance status of 0–1. The locations of primary
esophageal cancer removed by radical surgery varied,
with most lesions (62/83, 74.7%) locating at the middle
thoracic esophagus. Histology of primary tumor of all
the 83 patients was ESCC and 50 (60.2%) had G1-2
diseases. Forty-five patients had biopsies for recurrent
lesions with histology showing ESCC. Thirty-eight pa-
tients had recurrent disease diagnosed only by follow-
up CT but without biopsy, 18 had recurrent diseases of
station 1 nodes (10 with supraclavicular lymph nodes
and 8 with cervical paraesophageal nodes), 20 had
enlarged mediastinal station 2 and 4 nodes. The me-
dian interval time between surgery and CCRT was14 month (range, 2–88 months). Twenty patients
(24.1%) had anastomotic recurrence (AR) with or with-
out locoregional lymphadenopathy, 63 (75.9%) had
mediastinal and/or supraclavicular lymph node recur-
rence (LR). The most common involved lymph node
stations were 2R (26/83, 31.3%), 4R (19/83, 22.9%), 1R
(11/83, 13.3%) and 1 L (14/83, 16.9%). Median dose of
RT was 60 Gy (range, 56-68 Gy).
Table 3 Multivariate analysis of prognostic factors for
overall survival (n = 83)
Variable HR, 95% CI p value
Tumor response after CCRT (CR vs. non-CR) 5.10 (2.33-11.15) 0.000*
Concurrent chemotherapy (PF vs. TP) 0.39 (0.19-0.80) 0.010*
Note: *Multivariate analysis showed that tumor response after CCRT and
recurrence site had significant associations with OS.
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All patients were treated with 3D-CRT and concurrent
chemotherapy, 39 received concurrent PF, and 44 received
TP. With a median follow-up of 34 months (range, 2–
113 months), the 3-year overall survival (OS) of all the
patients was 51.8%, median OS time was 43.0 months.
Univariate analysis showed that tumor response after
CCRT (p = 0.000) and recurrence site (p = 0.028) had
significant associations with OS, while concurrent
chemotherapy (p = 0.090) showed a trend of association
with OS (Table 2). Clinical factors that were statistically
significant (p < 0.10) in a univariate analysis were ana-
lyzed further in a multivariate analysis with a stepwise
selection of variables. Only patients that had tumor
response after CCRT (p = 0.000) and concurrent chemo-
therapy (p = 0.010) were selected by a stepwise selection
as factors in the final models (Table 3). The overall
tumor response rate was 75.9% (63/83), with a complete
remission (CR) rate of 44.6% (37/83) and partial remission
(PR) rate of 31.3% (26/83). The 3-year OS of CR and non-
CR patients were 75.7% and 35.6%, while it was 59.2% for
patients received concurrent TP chemotherapy and 43.3%
for concurrent PF, respectively (Figure 1).
Failure pattern
Forty-one patients died during the observation period of
this study, 47 had progressive diseases after CCRT, 27 had
local failure (27/47, 57.4%), 18 had distant metastasis (18/
47, 38.3%) and 2 had both local and distant failures (2/47,
4.3%). The cause of death was related to progression of
disease in 36 patients and to unknown reasons in 5 pa-
tients. Table 4 demonstrated the failure pattern of CCRT.Table 2 Univariate analysis of prognostic factors of
overall survival (n = 83)
Variable HR, 95% CI p value
Sex (male vs. female) 0.70 (0.26-1.89) 0.477
Age (>55 yrs vs. ≤55 yrs) 0.67 (0.28-1.57) 0.344
ECOG performance status (0–1 vs. 2–3) 0.72 (0.27-1.86) 0.523
Primary tumor location (Upper vs.
Middle vs. Lower)
0.80 (0.40-1.61) 0.533
Radical surgery (Two-field vs. three-field) 1.31 (0.55-3.12) 0.540
Histology of primary tumor (G1-2 vs. G3-4) 1.05 (0.51-2.13) 0.905
Stage of primary tumor (I-II stage vs. III stage) 1.66 (0.88-3.12) 0.120
Time between surgery and RT
(>14 mon vs. ≤14 mon)
0.77 (0.34-1.77) 0.538
Recurrence site (AR vs. LR) 2.70 (1.06-6.88) 0.028*
RT dose(>60 Gy vs. ≤60 Gy) 1.26 (0.47-3.35) 0.648
Concurrent chemotherapy (PF vs. TP) 0.58 (0.31-1.09) 0.090#
Tumor response after CCRT (CR vs. non-CR) 4.20 (2.04-8.65) 0.000*
Note: *Univariate analysis showed that tumor response after CCRTand
recurrence site had significant associations with OS. # Univariate analysis
showed that concurrent chemotherapy showed a trend of association with OS.Lung (11/20) was the most common site of metastasis,
while other sites consisted in: bone (8/20), liver (5/20),
brain (2/20), and axillary node (1/20).
Toxicities
The most frequent toxicities observed were vomiting,
neutropenia, esophagitis, cough, and the large majority
of toxicity degrees were Grade (G) 1 or 2. G3 vomiting
was observed in 8 out of 39 patients (30.8%) who re-
ceived concurrent cisplatin plus 5-Fu, and in 10 out of
44 patients (33.3%) who received docetaxel plus cisplatin
regimen. G3 neutropenia was more common in docetaxel-
based group, where occurred in 11 out of 44 patients
(36.7%) compared with 6 out of 39 patients (23.1%) in cis-
platin plus 5-Fu group. G3 esophagitis had been observed
in 2 patients (2/39, 5.1%) in cisplatin plus 5-Fu group and
3 out of 44 patients (6.8%) in docetaxel-based group.
These 5 patients had a nasogastric feeding tube inserted
due to pain or difficulty in swallowing. No G3 or higher
cough was recorded among all the patients. There were
no treatment-related deaths and pneumonitis.
Discussion
CCRT has been established as a curative alternative for
the treatment of ESCC, conferring substantial improve-
ment in survival compared with RT alone. However,
the optimal treatment of recurrent ESCC after surgery
remained controversial. Some studies on the effectiveness
of radiotherapy with or without chemotherapy for treat-
ment of postoperative recurrent ESCC reported 2-year
survival rates of only 15-31% with short-term observation.
Lu et al. reported that the OS of all 73 recurrent ESCC pa-
tients was 46.7% and 4.7% at 1 and 3 years respectively,
and patients receiving CCRT had better OS than those re-
ceiving RT alone with 1-year OS 62.5% in CCRT group vs.
33.8% in RT alone group, 3-year OS 10.5% in CCRT group
vs. 0% in RT alone group [12]. A recent phase II study on
radiotherapy combined with nedaplatin and 5-Fu for post-
operative loco-regional recurrent ESCC showed improved
5-year OS of 27.0%. High objective response rate (76.7%)
for recurrent tumors was obtained in the study, suggesting
a potential benefit of concurrent chemotherapy [23].
In our study, the ESCC patients with localized recur-
rence treated by CCRT showed a promising improvement
of prognosis compared to the previous reports in which
the 3-year OS rate of all the patients was 51.8%, the
Figure 1 Overall survival of patients with different treatment responses and concurrent chemotherapy regimens (A) OS of patients
treated by different concurrent chemotherapy regimens, (B) OS of patients with different treatment responses.
Bao et al. Radiation Oncology 2013, 8:241 Page 5 of 8
http://www.ro-journal.com/content/8/1/241median OS time was 43.0 months, and the overall
tumor response rate was 75.9% (63/83). Similar to pri-
mary localized ESCC, prolonged survival is unlikely tobe achieved in patients who had postoperative recurrent
ESCC unless they have obtained a good local response
to initial chemoradiotherapy. In our study, an improvement
Table 4 Relationship between tumor response, concurrent chemotherapy and patterns of treatment failure (n = 83)
Characteristic Persistent local disease (%) Locoregional recurrence (%) Distant metastasis (%) Multiple failures (%)
Tumor response
CR (n = 37) 0 (0%) 6 (16.2%) 5 (13.5%) 1 (2.7%)
Non-CR (n = 46) 9 (19.6%) 12 (26.1%) 13 (28.3%) 1 (2.2%)
Concurrent chemotherapy
PF (n = 39) 6 (15.4%) 12 (30.8%) 9 (23.1%) 1 (2.6%)
TP (n = 44) 3 (6.8%) 6 (13.6%) 9 (20.5%) 1 (2.3%)
Total (n = 83) 9 (10.8%) 18 (21.7%) 18 (21.7%) 2 (2.4%)
Bao et al. Radiation Oncology 2013, 8:241 Page 6 of 8
http://www.ro-journal.com/content/8/1/241in survival was observed in patients who obtained CR after
CCRT, with the 3-year OS of CR and non-CR patients be-
ing 75.7% and 35.6% (p = 0.000). Recent studies of pre-
operative CCRT followed by surgery showed that the
excellent prognosis were associated with the patients who
achieve a complete pathological response to preoperative
CCRT [24-26]. Although clinical CR after CCRT may not
be significantly correlated to pathologic CR [27], maximiz-
ing the CR rate is likely to increase the proportion of pa-
tients with most favorable outcome and potentially affect
survival of the group as a whole. In our study, it showed
that in the CR group (37 patients), 7 patients developed
in-field local recurrence and 6 patients had distant metas-
tases; while in the non-CR group (46 patients) 22 had local
recurrence and 14 had distant metastases. These results
suggested that the survival benefit in CR group mainly
came from the decrease of the rate of local recurrence.
Moreover, local recurrence might have a relationship with
the occurrence of distant metastasis.
Our results also demonstrated a benefit in survival for
patients treated with a regimen of docetaxel-based con-
current chemotherapy. The 3 year OS rate was 59.2%
for patients received concurrent TP chemotherapy and
43.3% for concurrent PF. The Swiss Group for Clinical
Cancer Research (SAKK) established a preoperative in-
duction schedule comprising docetaxel and cisplatin
followed by CCRT [28]. This schedule proved to be ef-
fective and feasible, resulting in a 3-year survival rate of
53%. Indeed, taxanes promote tubulin conjugation and
stabilize microtubule formation, thereby inhibiting mi-
tosis. In addition to their cytotoxic effect, taxanes also
act as excellent radiosensitizers, arresting the cell cycle
in the G2/M phase [29]. Multiple studies have examined
the use of docetaxel and platinum compounds as
radiosensitizers for esophageal cancer and neoadjuvant
chemotherapy, reporting high pathological CR rates
[30,31]. Zanoni et al. reported that the results of neo-
adjuvant concurrent radiotherapy with docetaxel, cisplatin,
and 5-Fu was a promising regimen, with a 41.9% patho-
logical CR rate and a good safety profile [32]. Encouraged
by few recent studies suggesting the efficacy of taxanes in
esophageal cancer, investigators performed a phase II trialto evaluate the feasibility and safety of docetaxel and cis-
platin in 5-FU and cisplatin-pretreated esophageal cancer.
A total of 38 patients were enrolled, and 35 patients were
available for evaluation. The median and total numbers of
cycles delivered were 3.5 (range, 1–9 cycles) and 162, re-
spectively. One patient (2.6%) achieved complete response,
12 (31.6%) achieved partial response, 12 (31.6%) had stable
disease, and 10 (26.3%) had progressive disease. The over-
all response rate was 34.2% (95% confidence interval, 19.6-
51.3). The median progression-free survival and overall
survival times were 4.5 ± 1.3 months (95% CI, 4.1-4.9)
and 7.4 ± 0.4 months (95% CI, 7.3-7.5), respectively. The
best results were observed in patients who had good
performance status at baseline and who had longer
treatment-free intervals after first-line chemotherapy
[33]. In our study, 10 out of 83 patients (12.0%) had
ECOG 2–3. Among them 6 patients received 2 cycles of
cisplatin and 5-fluorouracil concurrently with RT, and 4
patients received concomitant weekly docetaxel and cis-
platin for 4–6 weeks. This suggested that performance
status at baseline is an important issue in choosing a
concurrent chemotherapy regimen.
Another interesting finding in our study was that AR
patients had a better OS compared with LR patients
(3-year rate 74.4% vs. 43.6%, P = 0.028). Among the 20 AR
patients, 11 patients had recurrent lesion only at anasto-
mosis, 7 patients had anastomotic recurrence and one
station lymph node involvement, and 2 patients had anas-
tomotic recurrence and more than one stations lymph
node involvement. After CCRT, 1 patient developed in-
field local recurrence and 5 had distant metastases in the
20 AR patients; while 26 had local recurrence and 15 had
distant metastases among the 63 LR patients. The recur-
rent lesion in AR patients seemed to be more localized
and had less lymph node involvements. This might be-
cause the anastomotic recurrence is more likely to cause
dysphagia and be diagnosed earlier. Other than that, anas-
tomotic recurrence could be regarded as a second primary
cancer; the prognosis would be different from extensive
lymph node involvement.
The higher treatment response and local control rates
in this study compared with other published data might
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(the CTV comprised the anastomosis, supraclavicular,
and station 1–5 and 7 lymph nodes in order to involve
all the subclinical metastatic regions); 2) the use of 3D-
CRT technique (3D-CRT had better GTV high dose
coverage than two-dimensional conventional radiotherapy
(2DCRT) which had been used by most previous studies);
3) the higher irradiation dose (median dose in present
study was 60 Gy, range from 56 to 68 Gy. Zhang’s study
suggested that higher dose of 60 Gy could achieve better
local control) [34]. 4) 44 out of 83 (53.0%) patients
receive docetaxel-based concurrent chemotherapy. This
retrospective study has several limitations such as selec-
tion bias, various chemotherapy regimens, small study
numbers and short follow-up time. Moreover, instru-
mental diagnostic procedures such as endoscopic ultra-
sound (EUS) and positron emission tomography (PET)
were not used for a precise CR evaluation of the recur-
rent lesions after CCRT. However, our results revealed
that ESCC patients with postoperative localized recur-
rent disease could achieve promising improvement in
outcome when treated with CCRT and they have the
potential to be cured. Patients could benefit from proper
target definition, 3D-CRT technique and aggressive con-
current chemotherapy.
Conclusions
3D-CRT-based CCRT is effective and well-tolerated in
patients with recurrent ESCC; patients obtaining complete
remission after CCRT or receiving concurrent TP chemo-
therapy appeared to achieve long-term OS. Although local
and distant failures remained high in the whole group,
patients with localized disease could still benefit from
aggressive CCRT. Prospective studies are needed to val-
idate these predictive factors.
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